AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02309125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate progressive loading using gingival formers
Description: Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm).
Study NCT02309125 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: submerged healing
Description: the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: 5 mcgm/kg daily Monday through Friday weeks 3-14
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Description: 5 mcgm/kg daily Monday through Friday weeks 3-14
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: 4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trastuzumab
Description: 4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: 25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vinorelbine
Description: 25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: 5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
Study NCT00169104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
Study NCT04164797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar+chemoradiotherapy
Description: antiangiogenic drug+chemoradiotherapy
Study NCT04164797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy
Description: chemoradiotherapy
Study NCT01873118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RN-RHDS protocol
Description: The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
Study NCT01873118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RN-RHDS+PT-RHDS protocol
Description: The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
Study NCT01873118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RN-RHDS + PT-RHDS + NIAF
Description: The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
Study NCT02815033 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Study NCT02815033 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 11C or 18F-Choline PET/CT
Study NCT02815033 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whole body MRI
Study NCT02815033 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone scan
Study NCT01373034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Dietary Fiber
Description: Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
Study NCT01373034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice powder
Description: Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
Study NCT06017544 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: The T2DM affected by AMI will be referred for receiving PCI.
Study NCT02855801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: constant exercise
Study NCT00638365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001
Description: Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
Study NCT00638365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single-dose administered intravenously
Study NCT04302779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solid Model
Description: Cupcakes will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating drying and discrimination tests 'which is the stronger in drying'). Measuring mucoadhesion via protein content remaining in saliva samples following consumption of cupcakes.
Study NCT04302779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: To study the perception of whey protein beverages using repeated consumption sensory methods (e.g. rating mouthdrying over repeated sips of the drink).
Study NCT01132118 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
Study NCT04535908 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiotherapy in prostate cancer patients
Study NCT01455753 — intervention group
Intervention type: OTHER
Intervention: Functional Proximity
Description: Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.
Study NCT01455753 — intervention group
Intervention type: OTHER
Intervention: Base Proximity
Description: We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
Study NCT04552574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMR(Home meal replacement)-type omega-3-balanced diet
Description: A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
Study NCT00287118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
Study NCT02855801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Study NCT01189825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
Study NCT06101836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training intervention
Description: Trainees underwent a one-day training course (intervention) by consciously competent endoscopists who were physically remote consisting of interactive theoretical sessions and live sessions, where trainees performed colonoscopy in their local endoscopy unit receiving real-time instructions via a tele-conference monitor. Trainers and trainees not doing the colonoscopy, followed the procedure in real-time. KPIs were assessed on trainee-performed colonoscopies for 3 weeks prior and 4 weeks after the intervention.
Study NCT02703077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spyglass
Description: Endoscopic direct view of the bile ducts
Study NCT02855801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent exercise
Study NCT04133597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: social media stimuli (Line app)
Description: social media stimuli (Line app) with texting messages or calls
Study NCT00411723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTL1000 (recombinant T cell receptor ligand)
Description: Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
Study NCT00411723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RTL1000 Placebo
Description: Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
Study NCT04308876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy includes techniques applied to elbow joints and surrounding tissues
Study NCT04308876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
Study NCT04308876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises
Description: Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
Study NCT02762071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
Study NCT02762071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Nerve Block
Description: Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
Study NCT00549796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Patients undergo routine, clinically indicated PCI
Study NCT00549796 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: Patients undergo routine, clinically indicated PCI
Study NCT02594917 — intervention group
Intervention type: PROCEDURE
Intervention: Right Heart Catheterization
Description: Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
Study NCT02594917 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Test and control group will be asked to give 20 ml of blood samples
Study NCT02896569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical combination therapy
Study NCT01438242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genecept Assay
Description: Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
Study NCT01300247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
Study NCT01300247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
Study NCT01300247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
Study NCT01300247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
Study NCT02768792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pembrolizumab,
Description: Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
Study NCT04611568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational and training material
Study NCT04611568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational lecture
Study NCT04611568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive melanoma curriculum
Study NCT04611568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Campaign
Description: View digital media strategies
Study NCT04611568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT02279290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Mind Intervention (HMI)
Description: Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
Study NCT02279290 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Body Intervention (HBI)
Description: The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
Study NCT02783274 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Actis Total Hip System
Description: Total Hip Replacement and Hemi-hip Replacement
Study NCT03589846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grass S88 Muscle Stimulator
Description: The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
Study NCT03828513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula oxygen is applied
Description: Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
Study NCT03828513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula oxygen is not applied
Description: Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
Study NCT03587311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV
Study NCT03587311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT03587311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04524364 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed Field Ablation (PFA) Therapy
Description: Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
Study NCT01051635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP400
Description: Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
Study NCT01051635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP776
Description: Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
Study NCT02844816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT00371475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté-SR
Description: Paclitaxel-Eluting Coronary 38 mm Stent
Study NCT00371475 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS™ Express
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT02703077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon dilation of the papilla
Description: Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
Study NCT00565552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silicone gel (Dermatix®)
Description: The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
Study NCT01408212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~* Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~* Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)
Study NCT03205475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Coaching and Video Feedback Phase 1
Description: Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
Study NCT03205475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching in Phase 1
Description: Weekly coaching (live or telehealth)
Study NCT03205475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Coaching plus Intensive Refresher Course Phase 2
Description: Continue weekly coaching with senior trainer and add one week intensive refresher course
Study NCT02703077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EHL (electrohydraulic lithotripsy)
Description: With a probe a direct view lithotripsy will be performed
Study NCT02703077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP (Endoscopic retrograde cholangiopancreatography)
Description: Endoscopic procedure to identify and treat biliary diseases